



## ORIGINAL ARTICLE

## Investigate of Haemostatic and Fibrinolytic System Parameters Among Sick Cell Anaemia Patients in the Khartoum State

Elteleb G. Elnaim<sup>1\*</sup>, Samar Ibrahim<sup>1</sup>, Duaa Ahmed<sup>1</sup>, Rayan Aldaw<sup>1</sup>, Nagwa Salih<sup>1</sup>, Muna Musa<sup>1</sup>, Esraa Yosuf<sup>1</sup>, Samah A. Ali<sup>2</sup>, Hassan Abdallah Abdalrahim Hamed<sup>3</sup>, Enaam H. Mohammed<sup>4</sup>, Naser Eldin Bilal<sup>5</sup>

### ABSTRACT

**Introduction:** A sickle cell anaemia one of a haemoglobinopathy, which constituted as a model for genetically inherited disorders, the course of the disease involves may crises, the investigation of hemostatic components as fibrinogen and fibrinolysis as D-dimer, reflect the overall hemostatic status in the sickle cell anaemia patients.

**Aim:** To investigate hemostatic and fibrinolytic system parameters among sickle cell anaemia patients in the Khartoum state.

**Methods:** The study was conducted in Khartoum state, in Jafar Ibn Auf Reference Hospital for children as descriptive case-control, a laboratory-based study from 2017-18, specimens were collected randomly of the study population with irrespective to age and gender, blood draw in tri-sodium citrate container, the ethical and consent were obtained.

The fibrinogen level was estimated by CA51 semi-automated coagulation analyzer optically based, and the D-dimer were assayed by MISPA-i2, a nephelometric based, the results for each parameter were recorded and using statistical package for the social sciences (SPSS) software for analysis by independent T-test and the statistical significance > 0.05.

**Results:** A 100 participants, 50 as study group HbSS sickle cell anemic Sudanese child clinically and laboratory-confirmed and 50 healthy as the control group, in comparing a mean of fibrinogen show statistically insignificant (P value 0.645) study group  $291.1 \pm 107.8$  mg/dL and control group  $283.4 \pm 49.1$  mg/dL, but there was a significant difference in comparing a mean of D-dimer in study group  $0.56 \pm 0.33$   $\mu$ g/mL and control group  $0.33 \pm 0.14$  the P. value 0.00015.

**Conclusion:** The level of D-dimer may be used as a hypercoagulability biomarker in comparison to the level of fibrinogen level for sickle cell anaemia Sudanese child.

**Keywords:** D-dimer, Fibrinogen, Sickle cell anaemia, Sudanese child.

Indian J. Pharm. Biol. Res. (2020): <https://doi.org/10.30750/ijpbr.8.2.1>

### INTRODUCTION

Sickle cell anaemia is a general classical form of genetically inherited diseases, form abnormalities of hemoglobin structurally, the sickle affecting the erythrocytes directly in which the clinical manifestations arise from classical theory for the tendency of hemoglobin to polymerize and lead to deforming the affected erythrocytes in crescent shape.<sup>[1-10]</sup> A single nucleotide change in the beta-globin chain gene leading to a substitution of valine for glutamic acid at position six of beta-globin chain gene, the homozygous present as HbSS and heterozygous as HbAS known as sickle cell trait, the hemoglobin polymerization is associated with different pathophysiological fashion, including; vascular crisis, bone crisis, and aplastic crisis, the hemoglobin

<sup>3</sup>Haematology and Immunohaematology Department, Faculty of Medical Laboratory, Eldaein University, Sudan.

<sup>4</sup>Haematology and Immunohaematology Department, Faculty of Medical Laboratory Sciences, Khartoum University, Sudan.

<sup>5</sup>Central Laboratory, Ministry of Higher Education and Scientific Research, Sudan.

**Corresponding Author:** Elteleb G. Elnaim, Haematology, and Immunohaematology Department, Faculty of Medical Laboratory Sciences, Nile University, Sudan., E-Mail: [eltelebgafer@gmail.com](mailto:eltelebgafer@gmail.com)  
ORCID ID: 0000-0001-7005-8134

**How to cite this article:** Elnaim EG, Ibrahim S, Ahmed D, Aldaw R, Salih N, Musa M, Yosuf E, Ali SA, Hamed HAA, Mohammed EH, Bilal NE. Investigate of Haemostatic and Fibrinolytic System Parameters among Sick Cell Anaemia Patients in the Khartoum State. Indian J. Pharm. Biol. Res. 2020;8(2):1-5.

**Source of support:** Nil

**Conflict of interest:** None.

**Received:** 28/02/2020 **Revised:** 23/04/2020 **Accepted:** 30/04/2020

**Published:** 30/06/2020

<sup>1</sup>Haematology, and Immunohaematology Department, Faculty of Medical Laboratory Sciences, Nile University, Sudan.

<sup>2</sup>Haematology Department, Faculty of Medical Laboratory Sciences, University of Medical Sciences and Technology, Sudan.

polymerization was related to a reduction of iron and water content (cell dehydration), and increased erythrocytes density with persistent membrane damage, hemolysis and improved blood flow.<sup>[11-15]</sup>

The signs and symptoms of sickle cell anaemia, which vary from individual to another, and changed over time, include; anemic episodes, painful swelling of hands and feet, frequent infraction, delayed growth and visual problems<sup>[16-18]</sup> Sickle cell anaemia can lead to stroke: can occur if sickle cells blocking blood flow to .area of the brain. Acute chest syndrome, hyper pulmonary tension, organ damage, blindness and leg ulcer with gallstones and another symptom of sickle cell crisis or sickling crisis may be used to describe several independent acute conditions were occurring in sickle cell anaemia patients or in patients with sickle cell diseases.<sup>[19-22]</sup>

The vaso-occlusive crisis is caused by sickle shaped erythrocytes that obstruct capillaries and restrict blood flow to organ resulting in ischemia, pain, necrosis, and organ damage, and splenic sequestration crisis, because of its narrow vessels and function in clearing defective erythrocytes, the spleen is frequently affected. This spleen damage increases the risk of infection from encapsulated organisms, splenic sequestration crises are acute, painful enlargements of the spleen, caused by intrasplenic trapping of erythrocytes and resulting in a precipitous fall in hemoglobin level with the potential for hypovolemic shock), and a plastic crisis (are acute worsening of the patient's baseline anaemia, producing pale appearance, fast heart, and fatigue.<sup>[23-24]</sup> This crisis is normally triggered by parvovirus B19, which directly affects the production of erythrocytes by invading the erythrocyte precursors and multiplying in and destroying them and hemolytic crisis (acute accelerated drops in hemoglobin level), the erythrocytes break down at a faster rate. This is particularly common in patients with coexistent G6PD deficiency management is supportive, sometimes blood transfusion.<sup>[25]</sup>

Different laboratory investigations were screening, or confirmatory tests were coupled to determine the episodic characters for coming patients as newly diagnosed or follow-up coming, and different previous studies describe the hypercoagulability or thrombosis tendency by demonstrations of fibrinogen and D-dimer level in the sickle cell anaemia patients.<sup>[26-34]</sup>

## **MATERIALS AND METHODS**

A **study was** descriptive case-control–laboratory-based study, was conducted in the Jaffar Ibn Auf Reference Hospital, the period of study during December 2017 to

July 2018, a population of the study included 50 sickle cell anaemia child attending Jaffar Ibn Auf reference hospital as a study group, and 50 healthy children were irrespective to age and gender, specimens were collected 1.8 mL of venous blood randomly using a sterile disposable plastic syringe with tri-sodium vacationer through aseptic standard non-traumatic vein puncture technique then investigate blood parameters were done, the ethical consideration was obtained, and the statistical parameters by SPSS using independent t rest and statistical significance at p-value <0.05.

Platelets' poor plasma was prepared for each participant, and the estimation of fibrinogen and d-dimer proceeded.

Measuring of D-dimer based nephelometric assay reagent used for in vitro quantitative determination of fibrin degradation product D-dimer level, using MISPA-i2 device, the MISPA-i2 device well controlled, and a test procedure was clear in the kit leaflet, the reference interval for D-dimer > 0.5µg/mL most correctly reference range for childhood, and results were recorded and statistically analyzed.

Estimation of fibrinogen level was measured by semi-auto coagulation analyzer CA51, and was equipped with a precise pipette and test optically based, the device and reagents were well controlled a test procedure as clear in the kit leaflet, and a standard chart was established, the reference interval for fibrinogen 200-400mg/dL, results were recorded and statistically analyzed.


## **RESULTS**

Our study was composed of hundred participants fifty as a control group and fifty as a study group as sickle cell anemic Sudanese child, clinically and laboratory-confirmed, in the Table 1 show independent t-test statistical parameter the population study for D-dimer and fibrinogen level. Figures 1 and 2 show the scatter mean plotted present statistically acceptable results.


## **DISCUSSION**

The child with sickle cell anaemia surrounded by many risking events, if occur led to death, a study was established to measure the association of the D-dimer level as fibrin degradation product and the level of fibrinogen as one major hemostatic component, the sickle cell anaemia in Sudan as an African country with a high frequency of sickle cell gene in the different divers' ethnic groups and geographical area, this affected many children in our country.

Our study showed a significant association of the D-dimer level among sickle cell anaemia (HbSS), Sudanese child in compression of normal healthy, Sudanese child



**Figure 1:** Shows the mean difference of D-dimer in patients and control groups. (p-value 0.00015)



**Figure 2:** Shows the mean difference in fibrinogen levels in patients and control groups. (p-value 0.645)

**Table 1:** Shows the description of the mean value of the estimated D-dimer and fibrinogen

Tested parameter	Study population	Patient	Control	P. value
		mean ± SD	mean ± SD	
Fibrinogen level		291.11 ± 107.77	283.37 ± 49.05	0.64500
D-dimer level		0.56 ± 0.33	0.32 ± 0.14	0.00015

HbAA. The mean of D-dimer level show (study group  $0.56 \pm 0.33 \mu\text{g/mL}$  and control group  $0.33 \pm 0.14$ ), the p-value = 0.00015. This was agreed with a study done in Sudan by Mahdi *et al.* that shows the significant elevation in the mean level of D-dimer in the sickle cell anaemia patient ( $1847.47 \pm 2004.92 \text{ ng/mL}$ ) as compared to control group ( $238.0 \pm 166.0 \text{ ng/mL}$ ).<sup>[28]</sup> Our finding with a similar trend of the previous study done in different populations that reported the higher level of D-dimer amongst sickle cell patients as a fibrinolytic marker for hypercoagulability.<sup>[28]</sup>

Our finding of mean of D-dimer was conflicted with a study done in Nigeria by Ekwere, *et al.* that shows there was no elevation in the level of D-dimer as the mean difference between case and control,<sup>[34]</sup> the confliction may due to the unmatched geographical and environmental state.

Our study showed an insignificant association of the fibrinogen level among sickle cell anaemia (HbSS) Sudanese child in compression of normal healthy Sudanese child (HbAA), the mean of Fibrinogen level show (study group  $291.1 \pm 107.8 \text{ mg/dL}$  and control group  $283.4 \pm 49.1 \text{ mg/dL}$ ), the p-value 0.645, this was agree with study done by Ekwere *et al* that conclude there was insignificance difference of sickle cell case and normal group.<sup>[34]</sup>

Our finding was conflicted with Nilesh, *et al.* that perform the measuring of fibrinogen level in the Indian

sickle cell population the mean of fibrinogen level showed significant higher for Hb SS patient (mean  $522.24 \text{ mg/dL}$ ) as compared to normal Hb AA control (mean  $275.26 \text{ mg/dL}$ ).<sup>[35]</sup> Our findings disagreed with a study done by Buseri *et al.* in Nigeria for measuring fibrinogen level among sickle cell anaemia patients that show a significant raising in fibrinogen level of sickle cell anaemia patients than the control group.<sup>[26]</sup> The evidence of confliction in an increase of fibrinogen level may due to the fibrinogen indicate as inflammatory markers.

The study limitations were restricted with many factors like the sample size and the acceptance of subjects to participate in the study; other limitations may due to the reagent supplying and the cost-effectiveness.

## CONCLUSION

This study concluded the confirmed hypercoagulable status in the sickle cell anaemia with higher D-dimer levels among the Sudanese child sickle cell anaemia population in comparison with healthy control child groups. And the study was concluded the normal level of fibrinogen in Sudanese child sickle cell anaemia population.

Our recommendation to an overcalling program that covers the thrombotic tendency in the sickle cell anaemia patients as preventative as possible of pulmonary embolism

and more advanced sophisticated molecular genetics study established to decrease mortality and motility in the Sudanese sickle cell anaemia child.

#### **ACKNOWLEDGMENT**

A great thanks for Jaffar Ibn Auf laboratory staff, Dr. Yasser Kamal Mohamed Ali, and special thanks for Nile university, faculty of medical laboratory sciences.

#### **CONTRIBUTION OF AUTHORS**

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this the authors have equally contributed to this study.

#### **REFERENCES**

1. John, Wiley, Sons; Blood science principle and pathology, 2014. Ltd, The Pathology of red blood cells, p 90-91.
2. Wright JG, *et al.* Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels, *Br J Haematol.* 1997; 98(3): 627-631.
3. National Library of Medicine, [ghr.nlm.nih.gov/condition/sickle-cell-disease](http://ghr.nlm.nih.gov/condition/sickle-cell-disease), accessed on 01/March/2018
4. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. *Jama.* 2014; 312(10): 1033-1048.
5. Wang WC and Lukens JN. Sickle cell anaemia and other sickling syndromes in Lee R, Lukens J, Greer JP, Rodgers GM, Paraskevas F, Foerster J *Wintrobe's Clinical Hematology.* 1998;1346-1397.
6. Vinay K, Abbas AK, Fauston N, Aster JC. Robbins and Cotran Pathologic Basis of Disease, p33498- 33499). Elsevier 2009.
7. Olujohungbe A, Burnett *et al.* How I manage priapism due to sickle cell disease". *British Journal of Haematology* 2013;160(6): 754-765.
8. Glassberg J. Evidence-based management of sickle cell disease in the emergency department. *Emergency Medicine Practice.* 2011;13(8):1-20.
9. B Anie KA, Green J. Psychological therapies for sickle cell disease and pain". *The Cochrane Database of Systematic Reviews* 2015; CD001916.
10. Pearson HA. Sickle cell anaemia and severe infections due to encapsulated bacteria. *Journal of Infectious Diseases.* 1977;136 (Supplement 1):S25-30.
11. Wong WY, Powars DR, Chan L, Hiti A, Johnson C. Over turf G. Polysaccharide encapsulated bacterial infection in sickle cell anemia: a thirty year epidemiologic experience. *American Journal of Hematology.* 1992;39(3): 176-182.
12. Khatib R, Rabah R, Sarnaik SA. The spleen in the sickling disorders: an update. *Pediatric radiology.* 2009;39(1):17-22.
13. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. *Journal of Laboratory and Clinical Medicine.* 2001; 137(6): 398-407.
14. Mekontso Dessap A, Leon R, Habibi A, Nzouakou R, Roudot-Thoraval F, Adnot S, Godeau B, Galacteros F, Brun-Buisson C, Brochard L, Maitre B. Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease. *American journal of respiratory and critical care medicine.* 2008;177(6):646-653.
15. Paul RN, Castro OL, Aggarwal A, Oneal PA. Acute chest syndrome: sickle cell disease. *European journal of haematology.* 2011; 87(3): 191-207.
16. Famodu AA and Reid HL. Plasma fibrinogen levels in sickle cell disease. *Trop Geogr Med* 1987;39(1):36-38.
17. Slavov SN, Kashima S, Pinto AC, Covas DT. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. *FEMS Immunology and Medical Microbiology.* 2011;62(3): 247-262.
18. S Balgir R. Community expansion and gene geography of sickle cell trait and G6PD deficiency, and natural selection against malaria: experience from tribal land of India. *Cardiovascular and Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry- Cardiovascular and Hematological Agents).* 2012;10(1): 3-13.
19. Jadavji T, Prober CG. Dactylitis in a child with sickle cell trait. *Canadian Medical Association Journal.* 1985;132(7):814-815.
20. Worrall VT, Butera V. Sickle-cell dactylitis. *The Journal of bone and joint surgery. American volume.* 1976;58(8):1161-1163.
21. Miller ST. How I treat acute chest syndrome in children with sickle cell disease. *Blood, The Journal of the American Society of Hematology.* 2011;117(20):5297-5305.
22. James, William D.; Berger, Timothy G., *Andrews' Diseases of the Skin: clinical Dermatology.* Saunders, Elsevier, 2006. p. 847.
23. Turgeon ML. *Clinical hematology theory and procedures, fifth edition,* Lippincott Williams and Wilkin 2012s, Walters kluwer business, the principle and disorders of hemostasis and thrombosis, p. 410.
24. John N. A review of clinical profile in sickle cell traits. *Oman Medical Journal.* 2010;25(1): 3.
25. Setty BN, Rao AK, and Stuart MJ., Thrombophilia in sickle cell disease: the red cell connection. *Blood,* 2001;98: 3228-3233.

26. Buseri FI, Shokunbi WA, Jeremiah ZA. Plasma fibrinogen levels in Nigerian homozygous (HbSS) sickle cell patients. *Hemoglobin*. 2007;31(1): 89-92.
27. Fakunle EE, Eteng KI, Shokunbi WA. DD dimer levels in patients with sickle cell disease during bone pain crises and in the steady state. *Pathology and Laboratory Medicine International*. 2012;4: 21-25.
28. Alaeldin M.E.Abouh and Mahdi H.A.Bbdalla, D-Dimer level in Sudanese children with sickle cell anemia, *International Journal of Current Research* 2014;6(5): 6599-6601.
29. Francis RB. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. *Patho-physiology of Haemostasis and Thrombosis*. 1989;19(2): 105-111.
30. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. *ASH Education Program Book*. 2007;(1): 919-6.
31. Shah N, Thornburg C, Telen MJ, and Ortel TL. Characterization of the hypercoagulable state in patients with sickle cell disease. *Thromb. Res*. 2012;130: e241-e245.
32. Dar J, Mughal I, Hassan H, Al Mekki TE, Chapunduka Z, and Hassan IS. Raised D-dimer levels in acute sickle cell crisis and their correlation with chest X-ray abnormalities. *Ger Med. Sci*. 2010; 8:25.
33. Colombatti R, De BE, Bertomoro A, Casonato A, Pontara E, Omenetto E, Saggiorato G, Steffan A, Damian T, Cella G, Teso S, Manara R, Rampazzo P, Meneghetti G, Basso G, Sartori MT, and Sainati L. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. *PLoS*. 2013;8: e78801.
34. Ekwere T, Ogunro SP, Akanmu AS. Assessment of some plasma fibrinolytic proteins in sickle cell anaemia patients in steady state and in vaso-occlusive crises. *Journal of Applied Hematology*. 2013;4(4):131.
35. Noubouossie DF, Le PQ, Corazza F, Debaugnies F, Rozen L, Ferster A, Demulder A. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. *Am. J. Hematol*. 2012; 87: 145-149.